Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Lamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, Carvhalo L, Bezerra ROF, Borg P, Vietti Violi N, Vidal Trueba H, de Mestier L, Scaefer N, Baudin E, Sundin A, Costa F, Pavel M, Dromain C.
Lamarca A, et al.
Clin Cancer Res. 2019 Nov 15;25(22):6692-6699. doi: 10.1158/1078-0432.CCR-19-0963. Epub 2019 Aug 2.
Clin Cancer Res. 2019.
PMID: 31375514
Aim-1: explore treatment-induced changes in TGR (deltaTGR(3m-BL); paired T test), and Aim-2: validate TGR(3m) (<0.8%/m vs. 0.8%/m) as an early biomarker in an independent cohort (Kaplan-Meier/Cox regression). RESULTS: Of 785 patients screened, 127 were eligible. Mean (S …
Aim-1: explore treatment-induced changes in TGR (deltaTGR(3m-BL); paired T test), and Aim-2: validate TGR(3m) (<0.8%/m vs. 0.8%/m) as an …